MX2019009122A - ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI). - Google Patents

ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).

Info

Publication number
MX2019009122A
MX2019009122A MX2019009122A MX2019009122A MX2019009122A MX 2019009122 A MX2019009122 A MX 2019009122A MX 2019009122 A MX2019009122 A MX 2019009122A MX 2019009122 A MX2019009122 A MX 2019009122A MX 2019009122 A MX2019009122 A MX 2019009122A
Authority
MX
Mexico
Prior art keywords
osteogenesis imperfecta
methods
treating
treating osteogenesis
subject
Prior art date
Application number
MX2019009122A
Other languages
English (en)
Inventor
T Sampath Kuber
Lee Brendan
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50483613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019009122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2019009122A publication Critical patent/MX2019009122A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

La presente invención proporciona métodos para tratar y mejorar los síntomas de la osteogénesis imperfecta (OI) en un sujeto administrando al sujeto una cantidad terapéuticamente eficaz de un agente de unión que se une a factor de crecimiento transformante beta (TGFß).
MX2019009122A 2013-03-20 2015-09-18 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI). MX2019009122A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361803647P 2013-03-20 2013-03-20
US201361875399P 2013-09-09 2013-09-09
US201361883151P 2013-09-26 2013-09-26

Publications (1)

Publication Number Publication Date
MX2019009122A true MX2019009122A (es) 2019-09-16

Family

ID=50483613

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013402A MX369360B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).
MX2019009122A MX2019009122A (es) 2013-03-20 2015-09-18 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015013402A MX369360B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).

Country Status (27)

Country Link
US (4) US9598486B2 (es)
EP (3) EP2976359B2 (es)
JP (3) JP6483086B2 (es)
KR (1) KR102257138B1 (es)
CN (2) CN111000997A (es)
AU (1) AU2014235933B2 (es)
CA (1) CA2907422C (es)
CL (1) CL2015002801A1 (es)
DK (2) DK3312195T3 (es)
EA (1) EA032327B1 (es)
ES (2) ES2700238T5 (es)
HK (2) HK1213576A1 (es)
HR (2) HRP20181939T4 (es)
HU (1) HUE046702T2 (es)
IL (2) IL241461B (es)
LT (2) LT3312195T (es)
MX (2) MX369360B (es)
MY (1) MY172324A (es)
PH (2) PH12015501864B1 (es)
PL (2) PL2976359T5 (es)
PT (2) PT3312195T (es)
RS (2) RS58188B2 (es)
SG (2) SG10201701985YA (es)
SI (2) SI2976359T2 (es)
TW (1) TWI629995B (es)
UY (1) UY35493A (es)
WO (1) WO2014153435A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX369360B (es) * 2013-03-20 2019-11-06 Baylor College Medicine ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).
WO2018027329A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
CN106755395B (zh) * 2016-12-16 2020-05-12 山东第一医科大学(山东省医学科学院) Xi型成骨不全致病基因fkbp10的突变位点及其应用
TWI787230B (zh) * 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
WO2018134681A1 (en) * 2017-01-20 2018-07-26 Sanofi Anti-tgf-beta antibodies and their use
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
BR112021000065A2 (pt) 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
MX2023004725A (es) * 2020-10-23 2024-02-23 Hq Han Antagonistas bifuncionales del factor de necrosis tumoral alfa y del factor de crecimiento transformante beta y usos de los mismos.
BR112023022742A2 (pt) * 2021-05-07 2024-01-02 Baylor College Medicine Tratamento da osteogênese imperfeita moderada a grave
CN113501879B (zh) * 2021-06-30 2022-09-06 拜盖特生物科技(上海)有限公司 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
TW202334209A (zh) * 2021-11-01 2023-09-01 美商健臻公司 成骨不全症之治療
WO2024149381A1 (en) * 2023-01-13 2024-07-18 Shanghai Kaijin Biotechnology, Ltd Multi-specific polypeptide complexes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6716836A (es) * 1967-12-11 1969-06-13
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE338120T2 (de) * 1998-11-27 2006-09-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
HUE042689T2 (hu) * 2005-02-08 2019-07-29 Genzyme Corp TGFbéta elleni antitestek
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2632799A1 (en) 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
TW201934141A (zh) * 2007-02-09 2019-09-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
CA2683816A1 (en) * 2007-04-26 2008-11-06 President And Fellows Of Harvard College Assays for the identification of compounds that modulate bone formation and mineralization
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
BRPI0907220A2 (pt) * 2008-01-15 2019-02-26 Kalobios Pharmaceuticals, Inc. métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
JP2012524818A (ja) * 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
MX369360B (es) * 2013-03-20 2019-11-06 Baylor College Medicine ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).

Also Published As

Publication number Publication date
EP2976359B1 (en) 2018-08-29
PH12019500261A1 (en) 2020-07-20
ES2763869T3 (es) 2020-06-01
US9598486B2 (en) 2017-03-21
RS58188B2 (sr) 2022-06-30
HK1253717A1 (zh) 2019-06-28
JP6677837B2 (ja) 2020-04-08
HRP20181939T4 (hr) 2022-05-13
CA2907422C (en) 2021-08-31
TW201524515A (zh) 2015-07-01
PH12015501864A1 (en) 2015-12-07
RS58188B1 (sr) 2019-03-29
EP2976359A1 (en) 2016-01-27
EA201591843A1 (ru) 2016-01-29
CN105229028B (zh) 2019-11-08
US20190389943A1 (en) 2019-12-26
EP3312195A1 (en) 2018-04-25
MX369360B (es) 2019-11-06
EP3312195B1 (en) 2019-10-09
EP2976359B2 (en) 2022-03-23
MX2015013402A (es) 2016-01-08
LT3312195T (lt) 2020-01-10
LT2976359T (lt) 2018-12-27
JP6483086B2 (ja) 2019-03-13
HRP20192277T1 (hr) 2020-03-06
MY172324A (en) 2019-11-21
PT3312195T (pt) 2019-12-23
DK2976359T3 (da) 2019-01-02
PH12019500261B1 (en) 2020-07-20
BR112015023905A2 (pt) 2017-10-24
HK1213576A1 (zh) 2016-07-08
IL241461A0 (en) 2015-11-30
IL287915A (en) 2022-01-01
JP2019089826A (ja) 2019-06-13
KR102257138B1 (ko) 2021-05-26
IL241461B (en) 2021-12-01
SI2976359T1 (sl) 2019-03-29
NZ712353A (en) 2021-04-30
US20160031979A1 (en) 2016-02-04
PL2976359T5 (pl) 2022-07-18
CN111000997A (zh) 2020-04-14
SI2976359T2 (sl) 2022-05-31
WO2014153435A1 (en) 2014-09-25
AU2014235933A1 (en) 2015-10-01
CL2015002801A1 (es) 2016-08-12
UY35493A (es) 2014-11-28
SG11201506683XA (en) 2015-09-29
JP7016113B2 (ja) 2022-02-04
PH12015501864B1 (en) 2015-12-07
CN105229028A (zh) 2016-01-06
DK3312195T3 (da) 2020-01-06
JP2016519093A (ja) 2016-06-30
US20170247439A1 (en) 2017-08-31
PL2976359T3 (pl) 2019-03-29
JP2020109110A (ja) 2020-07-16
EP3640260A1 (en) 2020-04-22
US10377819B2 (en) 2019-08-13
US11230595B2 (en) 2022-01-25
TWI629995B (zh) 2018-07-21
EA032327B1 (ru) 2019-05-31
CA2907422A1 (en) 2014-09-25
HUE046702T2 (hu) 2020-03-30
SG10201701985YA (en) 2017-04-27
DK2976359T4 (da) 2022-06-13
SI3312195T1 (sl) 2020-02-28
PT2976359T (pt) 2018-12-05
ES2700238T5 (es) 2022-05-20
AU2014235933B2 (en) 2019-01-24
RS59673B1 (sr) 2020-01-31
KR20150132262A (ko) 2015-11-25
US20220195025A1 (en) 2022-06-23
ES2700238T3 (es) 2019-02-14
PL3312195T3 (pl) 2020-04-30
HRP20181939T1 (hr) 2019-01-25

Similar Documents

Publication Publication Date Title
PH12019500261A1 (en) Methods for treating osteogenesis imperfecta
PH12015502075A1 (en) Treatment of cataplexy
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2020009260A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2015017970A (es) Metodos para tratar la poliposis nasal mediante la administracion de un antagonista de il-4r.
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
MX2013012572A (es) Anticuerpos anti-cd40 y metodos de uso.
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
GB201112145D0 (en) Means and methods for the treatment of pathological angiogenesis
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
MX354989B (es) Regimenes de tratamiento.
IN2014DN07989A (es)
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
AR095700A1 (es) Métodos para el tratamiento de la osteogénesis imperfecta
MX2013006633A (es) Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes.
WO2013158698A3 (en) Method treating scleroderma
WO2014151230A3 (en) Method of treating granulomatosis with polyangiitis
IN2013MU02486A (es)